Member Info for bigbench

LOL

remember NYCT 36 bagged in under 3 months!

Your red panties? ;-0

Give it a few weeks and you could triple it. ;-0

To be honest il be expecting more than 40p

showing 90 -95 to open on ADVFN.

I certainly expect the 83p from last week to be well and truly smashed this week.. £1...£1.50 must be the norm and don't forget the ex boss said last week on ADVFN the company was well under valued.

£15 quid would be nice but let's not get to ahead of ourselves .... £1 will do for starters. ;-0

Maybe RNS @7 am..? The website is updated with a "coming soon" heading so news can't be far that's for sure. Well worded RNS could triple the SP in an instant.

Let's hope so!

If RNS is as positive as we hope then the -10% will turn to +150%

Exactly thats why constant repetive multiple testing for everyone onthe planet until the virus is hunted down and indivuals isolated till the pass away or recover..in which acse they will need to be tested a few time and be negative before having the all clear.
In China 91 hospitalised patients who tested positive.. then recovered.. then tested negative .. 2 weeks later positive again.

Full article on skynews website...

Coronavirus: Currently 'no evidence' that COVID-19 survivors have immunity, WHO warns
Epidemiologists warn there is no proof that antibody tests can show if someone who has been infected cannot be infected again.

Plenty or articles from scientists saying there are at least 8 strains of this and its mutating all the time

Full article on skynews website...

Coronavirus: Currently 'no evidence' that COVID-19 survivors have immunity, WHO warns
Epidemiologists warn there is no proof that antibody tests can show if someone who has been infected cannot be infected again.

Constant testing will become the norm, Ocardo boss has spent £1.5m on kits for staff other employers will no doubt follow.. every hospital admission will be tested on entry and several times whilst they are in... police, fire, ambulance will all have to be constantly tested... multiple that around the world and make your own numbers up.. unlimited.

… will only want UK tested and approved products after a report of sub standard kits being bought in from China..seen that report a few times saying £17m spent and they don't work.

Another point to note is our massive manufacturing potential of 10'000 test kits per hour...not many companies involved can match that out put.

Coronavirus test development

With a rapid global shift of healthcare emphasis towards testing and treatment of COVID-19, the Company has refocussed a significant part of its core resources towards development of two SARS-COV-2 tests.

The Company’s first assay, already in development, is an instrument-agnostic molecular assay (the Genedrive® 96 SARS-COV-2 test) that can be performed on a variety of high throughput molecular testing platforms already installed in many laboratories around the world. The test will determine if a patient has an active SARS-COV-2 infection. The Company anticipates that a clinically validated high throughput test format could be available in approximately eight weeks.

The Genedrive® 96 SARS-COV-2 test is designed as a one-step, ready-to-go freeze dried assay. Based on discussions with sizable third party suppliers the Company expects it could have the ability to ramp quickly to high production volumes of over 10,000 tests per hour, and thus this could be both a material revenue generator for the Company and significant contributor to addressing the global pandemic. Freeze dried assays require no refrigeration and are stable in transport, which is a significant logistical advantage for rapid shipment and global distribution.

A second test will also be developed by the Company where it will adapt its formulations to run on the Genedrive® instrument platform to provide a rapid point-of-care SARS-COV-2 test to allow testing outside of the main hospital


environment in places such as clinics, intensive care units, or where rapid and accurate testing for SARS-COV-2 might be required. The rationale for the two-stage development is that the testing, logistics, validation, and trial work to provide testing on a turnkey instrument system like Genedrive® takes additional time compared to an agnostic assay format.

The Company believes that the principal risks on SARS-COV-2 assays development are related to business continuity and supply chain robustness for raw materials in the market, as opposed to technical challenges. The Company is also actively seeking development partners, distributors and non-dilutive funding to support the most rapid development possible.

That's anyones call longrun…. we touched 83p in the week on no news so if a positive RNS lands early next week id expect 100%+ uplift from this price point... the reason is there are only 35m shares in total here and far less in free float so jumps seem to be amplified....combine that with the relatively small £20m Mcap is ripe for a massive jump in my humble opinion. NYCT went from 14p to over £5 in a matter of 10weeks or so... so GDR at 58p its a steal in my view.

Bit more info from website which some I think have over looked...especially the last line…seeking partners and Non dilutive funding... great stuff.